guild wars 2 gold

0愛的鼓勵 0訂閱站台

Medical biology: looking sweet in the tsunami of "Noah's Ark" 1, sweet "tsunami" attack, creating blockbuster products seedling fertile ground for diabetes is the world's top five killers, IMS the next 10-20 years diabetes prevalence will first of all diseases, especially in the Asian region gw2 power leveling, and compound growth will rapidly increase in the number of patients with diabetes mellitus. IMS forecasts number patients with diabetes by 2020 China will be up to 1.500 million, for diabetic patients than any other nation in the world. 2010 global diabetes drug market size up to 34.43 billion, near five-year compound annual growth rate of 12.7%, significantly higher than other diseases drugs market growth over the same period, was born 5 heavy global sales of more than $ 2 billion of products and enterprises. 2010 sample hospitals diabetesDrug market size exceed 10 billion, nearly five-year compound annual growth rate of nearly 15%, higher than the world growth over the same period. 2 treatment, diabetes market: foreign brand-led domestic enterprises to accelerate the pace of followers, hypoglycemic Chinese patent medicine potential should not be underestimated to biguanides, Alpha-glucosidase inhibitors, represented most of the subdivision categories controlled by foreign companies, domestic enterprises are not dominantPotential. However there are a few varieties such as CR shuanghe area of the sugar in the varieties of gliquidone monopoly; Huadong medicine pioglitazone kasiping this variety market share topped; voglibose variety foreign-owned and domestic companies in the field share markets; another category of concern is similar to GLP-1 and DPP-IV inhibitors class. Although the currentDomestic no Aissey peptide and production enterprises in the West he listed Ting similar products, but there is no doubt these two categories has been the focus of major domestic enterprises reserve new products. Proprietary Chinese medicines in the treatment of chronic disease kinds of natural advantage in terms of traditional Chinese medicine of hypoglycemic agents in the future growth of the internal factors that brought treated by traditional Chinese medicine theory of evidence-based medicine to promote new ways of development of diabetes, is expected to drive area of hypoglycemic Chinese patent medicines coming Festival"Made in China" blockbuster products. 3, continuous glucose monitoring systems markets: domestic brands prospects for import substitution of domestic brand blood glucose monitoring system with foreign brands in the technology gap is unlikely, but price/performance advantage significantly. Current biological and three Novartis Beijing Yi became representative of domestic brand blood glucose monitoring systems market share to around 30%, as blood glucose self regulatoryMeasuring rate of promotion, continuous glucose monitoring system in China broad market space. We believe that the domestic brands achieving import substitution is a big trend for foreign brands. Driver main is Medicare controlling pressure and consumer wishes for patients in rural and less developed areas. We are particularly optimistic about complete product line, has a wide coverage of marketing outreach network, channels, strong innovation capacity of enterprises.In the general trend of the domestic brands of import substitution, such enterprises access to development opportunities guild wars 2 power leveling. 4, investment strategy and recommendations-search sweet tsunami of "Noah's Ark" by case analysis of eight companies, we believe that the rich product line, with exclusive varieties, marketing management innovation ability, research and development outstanding enterprise worth the long-term bullish. Recommendations focus on Eastern medicine,Ridge pharmacy, three Nobel bio and sustained attention hengrui medicine, China resources investment opportunities in companies such as double-crane, diving medical. Risk warning: endocrine products administrative price risk; part of progress of research and development of new products do not achieve expectations.